Abstract
Treatment with tenofovir sometimes leads to non-reversible kidney and/or bone diseases. Factors associated with these drug-related adverse events are poorly characterized. Our objective was to investigate such factors in patients treated long term with daily tenofovir. One-hundred Caucasian HIV-positive patients with basal creatinine clearance >80 mL/min treated with tenofovir for at least 6 months and with at least one assessment of tenofovir plasma trough concentrations were considered. Tenofovir-associated adverse events were defined as the appearance of pathological proteinuria, worsening of renal function or bone demineralization. By multivariate regression analysis, we found that serum creatinine (p = 0.003) and body weight (p = 0.002) were the factors independently associated with plasma tenofovir concentrations. In particular, women with body weight50 Kg (160±93 vs.71±52 ng/mL, p
| Original language | English |
|---|---|
| Article number | e80242 |
| Journal | PLoS One |
| Volume | 8 |
| Issue number | 12 |
| DOIs | |
| Publication status | Published - Dec 2 2013 |
Fingerprint
ASJC Scopus subject areas
- Agricultural and Biological Sciences(all)
- Biochemistry, Genetics and Molecular Biology(all)
- Medicine(all)
Cite this
Low body weight in females is a risk factor for increased tenofovir exposure and drug-related adverse events. / Gervasoni, Cristina; Meraviglia, Paola; Landonio, Simona; Baldelli, Sara; Fucile, Serena; Castagnoli, Laura; Clementi, Emilio; Riva, Agostino; Galli, Massimo; Rizzardini, Giuliano; Cattaneo, Dario.
In: PLoS One, Vol. 8, No. 12, e80242, 02.12.2013.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Low body weight in females is a risk factor for increased tenofovir exposure and drug-related adverse events
AU - Gervasoni, Cristina
AU - Meraviglia, Paola
AU - Landonio, Simona
AU - Baldelli, Sara
AU - Fucile, Serena
AU - Castagnoli, Laura
AU - Clementi, Emilio
AU - Riva, Agostino
AU - Galli, Massimo
AU - Rizzardini, Giuliano
AU - Cattaneo, Dario
PY - 2013/12/2
Y1 - 2013/12/2
N2 - Treatment with tenofovir sometimes leads to non-reversible kidney and/or bone diseases. Factors associated with these drug-related adverse events are poorly characterized. Our objective was to investigate such factors in patients treated long term with daily tenofovir. One-hundred Caucasian HIV-positive patients with basal creatinine clearance >80 mL/min treated with tenofovir for at least 6 months and with at least one assessment of tenofovir plasma trough concentrations were considered. Tenofovir-associated adverse events were defined as the appearance of pathological proteinuria, worsening of renal function or bone demineralization. By multivariate regression analysis, we found that serum creatinine (p = 0.003) and body weight (p = 0.002) were the factors independently associated with plasma tenofovir concentrations. In particular, women with body weight50 Kg (160±93 vs.71±52 ng/mL, p
AB - Treatment with tenofovir sometimes leads to non-reversible kidney and/or bone diseases. Factors associated with these drug-related adverse events are poorly characterized. Our objective was to investigate such factors in patients treated long term with daily tenofovir. One-hundred Caucasian HIV-positive patients with basal creatinine clearance >80 mL/min treated with tenofovir for at least 6 months and with at least one assessment of tenofovir plasma trough concentrations were considered. Tenofovir-associated adverse events were defined as the appearance of pathological proteinuria, worsening of renal function or bone demineralization. By multivariate regression analysis, we found that serum creatinine (p = 0.003) and body weight (p = 0.002) were the factors independently associated with plasma tenofovir concentrations. In particular, women with body weight50 Kg (160±93 vs.71±52 ng/mL, p
UR - http://www.scopus.com/inward/record.url?scp=84891760370&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84891760370&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0080242
DO - 10.1371/journal.pone.0080242
M3 - Article
VL - 8
JO - PLoS One
JF - PLoS One
SN - 1932-6203
IS - 12
M1 - e80242
ER -